Literature DB >> 26359549

Cyclic Peptides Incorporating Phosphotyrosine Mimetics as Potent and Specific Inhibitors of the Grb7 Breast Cancer Target.

Gabrielle M Watson, Menachem J Gunzburg, Nigus D Ambaye, William A H Lucas, Daouda A Traore, Ketav Kulkarni, Katie M Cergol1, Richard J Payne1, Santosh Panjikar2, Stephanie C Pero3, Patrick Perlmutter, Matthew C J Wilce, Jacqueline A Wilce.   

Abstract

The Grb7 adaptor protein is a therapeutic target for both TNBC and HER2+ breast cancer. A nonphosphorylated cyclic peptide 1 (known as G7-18NATE) inhibits Grb7 via targeting the Grb7-SH2 domain, but requires the presence of phosphate ions for both affinity and specificity. Here we report the discovery of malonate bound in the phosphotyrosine binding pocket of the apo-Grb7-SH2 structure. Based on this, we carried out the rational design and synthesis of two analogues of peptide 1 that incorporate carboxymethylphenylalanine (cmF) and carboxyphenylalanine (cF) as mimics of phosphotyrosine (pY). Binding studies using SPR confirmed that affinity for Grb7-SH2 domain is improved up to 9-fold over peptide 1 under physiological phosphate conditions (KD = 2.1-5.7 μM) and that binding is specific for Grb7-SH2 over closely related domains (low or no detectable binding to Grb2-SH2 and Grb10-SH2). X-ray crystallographic structural analysis of the analogue bearing a cmF moiety in complex with Grb7-SH2 has identified the precise contacts conferred by the pY mimic that underpin this improved molecular interaction. Together this study identifies and characterizes the tightest specific inhibitor of Grb7 to date, representing a significant development toward a new Grb7-targeted therapeutic.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26359549     DOI: 10.1021/acs.jmedchem.5b00609

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Enhancing the Bioactivity of Bicyclic Peptides Targeted to Grb7-SH2 by Restoring Cell Permeability.

Authors:  Natasha P Sturre; Rhys N Colson; Neelam Shah; Gabrielle M Watson; Xue Yang; Matthew C J Wilce; John T Price; Jacqueline A Wilce
Journal:  Biomedicines       Date:  2022-05-16

2.  A trapped human PPM1A-phosphopeptide complex reveals structural features critical for regulation of PPM protein phosphatase activity.

Authors:  Subrata Debnath; Dalibor Kosek; Harichandra D Tagad; Stewart R Durell; Daniel H Appella; Roderico Acevedo; Alexander Grishaev; Fred Dyda; Ettore Appella; Sharlyn J Mazur
Journal:  J Biol Chem       Date:  2018-03-30       Impact factor: 5.157

3.  Direct Interaction between Calmodulin and the Grb7 RA-PH Domain.

Authors:  Gabrielle M Watson; Jacqueline A Wilce
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

4.  Unexpected involvement of staple leads to redesign of selective bicyclic peptide inhibitor of Grb7.

Authors:  Menachem J Gunzburg; Ketav Kulkarni; Gabrielle M Watson; Nigus D Ambaye; Mark P Del Borgo; Rebecca Brandt; Stephanie C Pero; Patrick Perlmutter; Matthew C J Wilce; Jacqueline A Wilce
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

5.  Insight into the Selectivity of the G7-18NATE Inhibitor Peptide for the Grb7-SH2 Domain Target.

Authors:  Gabrielle M Watson; William A H Lucas; Menachem J Gunzburg; Jacqueline A Wilce
Journal:  Front Mol Biosci       Date:  2017-09-26

6.  Shortened Penetratin Cell-Penetrating Peptide Is Insufficient for Cytosolic Delivery of a Grb7 Targeting Peptide.

Authors:  Gabrielle M Watson; Ketav Kulkarni; Rebecca Brandt; Mark P Del Borgo; Marie-Isabel Aguilar; Jacqueline A Wilce
Journal:  ACS Omega       Date:  2017-02-23

7.  Evaluation of Cyclic Peptide Inhibitors of the Grb7 Breast Cancer Target: Small Change in Cargo Results in Large Change in Cellular Activity.

Authors:  Jianrong Sang; Ketav Kulkarni; Gabrielle M Watson; Xiuquan Ma; David J Craik; Sónia T Henriques; Aaron G Poth; Aurélie H Benfield; Jacqueline A Wilce
Journal:  Molecules       Date:  2019-10-17       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.